The use of preexposure treatments for HIV prophylaxis

References

• UNAIDSAIDS Epidemic UpdateGenevaUNAIDS/WHO2009
   Google Scholar
• CohenMSChenYQMcCauleyMfor HPTN 052 Study TeamPrevention of HIV-1 infection with early antiretroviral therapyN Engl J Med20113656493505 Epub July 18, 201121767103
   PubMed Web of Science ®Google Scholar
• AnglemeyerARutherfordGWEggerMSiegfriedNAntiretroviral therapy for prevention of HIV transmission in HIV-discordant couplesCochrane Database Sys Rev2011115CD009153
   Google Scholar
• VolminkJSiegfriedNLvan Der MerweLBrocklehurstPAntiretrovirals for reducing the risk of mother-to-child transmission of HIV infectionCochrane Database Sys Rev20071CD003510
   PubMed Web of Science ®Google Scholar
• SmithDKGrantRMWeidlePJLanskyAMerminJFentonKAInterim guidance: Preexposure prophylaxis for the prevention of HIV infection in men who have sex with menMMWR Morb Mortal Wkly Rep2011603656821270743
   PubMedGoogle Scholar
• HallHISongRRhodesPfor HIV Incidence Surveillance GroupEstimation of HIV incidence in the United StatesJAMA200830052052918677024
   PubMed Web of Science ®Google Scholar
• KelesedisTLandovitzRJPreexposure prophylaxis for HIV preventionCurr HIV/AIDS Rep201189410321465112
   PubMedGoogle Scholar
• SteinZAHIV prevention: the need for methods women can useAm J Pub Health1990804604622316768
   PubMed Web of Science ®Google Scholar
• CutlerBJustmanJVaginal microbicides and the prevention of HIV transmissionLancet Infect Dis2008868569718992405
   PubMed Web of Science ®Google Scholar
• Pearce-PrattRPhillipsDSulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1Biol Reprod19965411731828838015
   PubMed Web of Science ®Google Scholar
• Scordi-BelloIMosoianAHeCCandidate sulfonated topical microbicides; comparison of antihuman immunodeficiency virus activities and mechanisms of actionAntimicrob Agents Chemother2005493607361516127029
   PubMed Web of Science ®Google Scholar
• RusconiSMoonisMMerrillSPNaphtalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activitiesAntimicrob Agents Chemother1996402342368787913
   PubMed Web of Science ®Google Scholar
• BourneNBernsteinDIrelandJSonderfanAJProfyATStanberryLRThe topical microbicide PRO 2000 protects against genital herpes in a mouse modelJ Infect Dis199918020320510353881
   PubMed Web of Science ®Google Scholar
• RamjeeGKamaliAMcCormackSThe last decade of microbicide trials in Africa: from hypothesis to factsAIDS201024Suppl 4S40S4921042052
   PubMed Web of Science ®Google Scholar
• Skoler-KarpoffSRamjeeGAhmedKEfficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised double-blind placebo-controlled trialLancet20083721977198719059048
   PubMed Web of Science ®Google Scholar
• Van DammeLGovindenRMirembeFfor CS Study GroupLack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmissionN Engl J Med200835946347218669425
   PubMed Web of Science ®Google Scholar
• HalpernVOgunsolaFObungeOEffectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in NigeriaPLoS One2008311e3784 Epub November 21, 200819023429
   PubMed Web of Science ®Google Scholar
• Abdool KarimSRaichardsonBARamjeeGfor HIV Prevention Trials Network (HPTN) 035 Study TeamSafety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in womenAIDS201125795796621330907
   PubMed Web of Science ®Google Scholar
• McCormackSRamjeeGKamallAPro2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3 randomised, double-blind, parallel group trialLancet2010376974913291337 Epub September 17, 201020851460
   PubMed Web of Science ®Google Scholar
• MesquitaPMCheshenkoNWilsonSSDisruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safetyJ infect Dis200920059960819586414
   PubMed Web of Science ®Google Scholar
• Van DammeLRamjeeGAlaryMfor COL-1492 Study GroupEffectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomized controlled trialLancet200236097197712383665
   PubMed Web of Science ®Google Scholar
• CranageMSharpeSHerreraCPrevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gelPLoS Med20085e15718684007
   PubMed Web of Science ®Google Scholar
• ParikhUDobardCSharmaSComplete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabineJ Virol200983201035810365 Epub August 5, 200919656878
   PubMed Web of Science ®Google Scholar
• AbdoolKQAbdool KarimSSFrolichJAfor CAPRISA 004 Trial GroupEffectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in womenScience2010329599611681174 Epub July 19, 201020643915
   PubMed Web of Science ®Google Scholar
• NelAMCoplanPVan de WijgertJHSafety, tolerability and systemic absorption of dalpivirine vaginal microbicide in healthy HIV-negative womenAIDS2009231531153819550287
   PubMed Web of Science ®Google Scholar
• SchwartzJLKovalevskyGLaiJ-JA randomized six-day study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitorSex Trans Dis2008354414419
   Web of Science ®Google Scholar
• AntonPASaundersTElliotJFirst phase 1 double-blind, placebo-controlled randomized rectal microbicide using UC781 gel with a novel index of ex vivo efficacyPLoS One201169e23243 Epub September 28, 201121969851
   PubMed Web of Science ®Google Scholar
• IPMglobal.org [homepage on the Internet]MarylandInternational Partnership for Microbicidesc2002–11 Available from: http://www.ipmglobal.org/publications-media/novel-technology-microbicide-ringAccessed December 8, 2011
   Google Scholar
• VeazeyRSKlassePJSchaderSMProtection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus cell fusionNature200543899102 Epub October 30, 200516258536
   PubMed Web of Science ®Google Scholar
• VeazeyRSKetasRJDufourJProtection of rhesus monkeys from vaginal infection by vaginally-delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptorJ Infect Dis2010102573974420629537
   PubMed Web of Science ®Google Scholar
• NeffCPKurisuTNdoloTFoxKAkkinaRA topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu micePloS One201166e20209 Epub June 1, 201121673796
   PubMed Web of Science ®Google Scholar
• CohenMSHIV and sexually transmitted diseases: lethal synergyTop HIV Med200412410410715516707
   PubMedGoogle Scholar
• SmithDKGrohskopfLABlackRJfor US Department of Health and Human ServicesAntretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the US Department of Health and Human ServicesMMWR Recomm Rep200554RR-212015660015
   PubMedGoogle Scholar
• McMichaelAJBorrowPTomarasGDGoonetillekeNHaynesBFThe immune response during acute HIV-1 infection: clues for vaccine developmentNat Rev Immunol201010112320010788
   PubMed Web of Science ®Google Scholar
• RomanelliFMurphyBSystemic preexposure prophylaxis for human immunodeficiency virus infectionPharmacotherapy201030101021103020874040
   PubMed Web of Science ®Google Scholar
• DumondJBYehRFPattersonKBAntiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxisAIDS2007211899190717721097
   PubMed Web of Science ®Google Scholar
• CohenMSGayCKashubaABlowerSPaxtonLNarrative review: Antiretroviral therapy to prevent the sexual transmission of HIV-1Ann Intern Med200714659160117438318
   PubMed Web of Science ®Google Scholar
• BrownKCPattersonKBMaloneSASingle and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative menJ Infect Dis2011203101484149021502084
   PubMed Web of Science ®Google Scholar
• DumondJBPattersonKBPechaALMaraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative womenJ Acquir Immune Defic Syndr200951554655319546811
   PubMed Web of Science ®Google Scholar
• ClavelCPeytavinGTubianaRRaltegravir concentrations in the genital tract of HIV-1 infected women with a raltegravir-containing regimen (DIVA 01 study)Antimicrob Agents Chemother20115563018302121444705
   PubMed Web of Science ®Google Scholar
• BarauCDelaugerreCDraunJHigh concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trialAntimicrob Agents Chemother2010542937939 Epub December 7, 200919995925
   PubMed Web of Science ®Google Scholar
• MolinaJMLamarcaAAndrade-Villanuevafor Study 145 TeamEfficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority studyLancet Infect Dis20121212723 Epub October 18, 201122015077
   PubMed Web of Science ®Google Scholar
• Van LunzenJMaggioloFArribasJROnce daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging randomised, phase 2b trialLancet Infect Dis Epub October 20, 2011
   Web of Science ®Google Scholar
• TsaiCCFollisKESaboAPrevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adeninineScience19952705239119711997502044
   PubMed Web of Science ®Google Scholar
• SubbaraoSOttenRARamosAChemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus given multiple virus challengesJ Infect Dis200619490491116960777
   PubMed Web of Science ®Google Scholar
• SubarraoSRamosAKimCDirect stringency comparison of two macaque models (single-high vs repeat-low) for mucosal HIV transmission using an identical anti-HIV chemoprophylaxis interventionJ Med Primatol2007364–523824317669212
   PubMed Web of Science ®Google Scholar
• García-LermaJGOttenRAQariSHPrevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovirPLoS Med200852e2818254653
   PubMed Web of Science ®Google Scholar
• García-LermaJGCongMEMitchellJIntermittent prophylaxis with truvada protects macaques from rectal SHIV infectionSci Transl Med201021414ra4
   PubMed Web of Science ®Google Scholar
• CongMYoungpairojASZhengQProtection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with TruvadaJ Virol2011851579337936 Epub June 1, 201121632769
   PubMed Web of Science ®Google Scholar
• VeazeyRSSpringerMSMarxPADufourJKlassePJMooreJPProtection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitorNat Med200511121293129416273102
   PubMed Web of Science ®Google Scholar
• DentonPWEstesJDSunZAnitretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT micePLoS Med200851e1618198941
   PubMed Web of Science ®Google Scholar
• DentonPWKriskoJFPowellDASystemic administration of anitretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT micePLoS One201051e882920098623
   PubMed Web of Science ®Google Scholar
• NeffCNdoloTTandonAHabuYAkkinaROral pre-exposure prophylaxis by raltegravir and maraviroc protects against vaginal HIV-1 transmission in a humanized mouse modelPloS One2010512e1525721203568
   PubMed Web of Science ®Google Scholar
• PetersonLTaylorDRoddyRTenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized placebo-controlled trialPLoS Clin Trials200725e2717525796
   PubMedGoogle Scholar
• GrantRMLamaJRAndersonPLfor iPrEx Study TeamPreexposure chemoprophylaxis for HIV prevention in men who have sex with menN Engl J Med20103632725872599 Epub November 23, 201021091279
   PubMed Web of Science ®Google Scholar
• ThigpenMCKebaabetswePMSmithDKfor the TDF2 Study GroupDaily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study [abstractWELBC01]From: 6th IAS Conference on HIV Pathogenesis, Treatment, and PreventionJuly 17–20, 2011Rome, ItalyInternational AIDS Society2011
   Google Scholar
• [No authors listed]Early end for FEM-Pr-EP HIV prevention trialAIDS Patient Care STDS201125638321612547
   PubMedGoogle Scholar
• BaetenJCelumCAntiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP study [abstract MOAX0106]From: 6th IAS Conference on HIV Pathogenesis, Treatment, and PreventionJuly 17–20, 2011Rome, ItalyInternational AIDS Society2011
   Google Scholar
• CohenMSChenYQMcCauleyMfor HPTN 052 Study TeamPrevention of HIV-1 infection with early antiretroviral therapyN Engl J Med20113656493505 Epub July 18, 201121767103
   PubMed Web of Science ®Google Scholar
• HendrixCMinnisAGudderaVfor MTN-001 Study TeamMTN-001: A phase 2 cross-over study of daily oral and vaginal TFV in healthy, sexually active women results in significantly different product acceptability and vaginal tissue concentrations [Abstract 35LB]From: 18th Conference on Retroviruses and Opportunistic InfectionsFebruary 27–March 2, 2011Boston, MA Available from: http://www.retroconference.org/2011/Abstracts/42418.htmAccessed December 26, 2011
   Google Scholar
• VeroneseFTurpinJAFeuerCBeyond 2010: Gaps, Challenges, and Priorities for the Future of Preclinical HIV Preexposure Prophylaxis (PrEP): Summary of the October 20–21, 2009 WorkshopAIDS Res Hum Retroviruses201026111820055588
   PubMed Web of Science ®Google Scholar
• HPTN Studies [study page on the Internet]HIV Prevention Trials Networkc2010 Available from http://ww.hptn.org/research_studies.aspAccessed November 1, 2011
   Google Scholar
• Avac.org [homepage on the Internet]New YorkAVAC: Global Advocacy for HIV Preventionc2011 Available from: http://www.avac.orgAccessed December 5, 2011
   Google Scholar
• AbbasULAndersonRMMellorsJWPotential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settingsJ Acquir Immune Defic Syndr200641563264116652038
   PubMed Web of Science ®Google Scholar
• PatelSMJohnsonSBelknapSMSevere adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individualsJ Acquir Immune Def Syndr2004352120125
   Web of Science ®Google Scholar
• Cdc.gov. Preliminary results from first safety study of daily tenofovir for HIV prevention among MSM find no significant concernsAtlanta, GACDC [updated December 8, 2011] Available from: (www.cdc.gov/hiv/prep/resources/factsheets/extended_PrEB-safety-trial.htm) July 23, 2010Accessed November 1, 2011
   Google Scholar
• LiuAVittinghoffEIrbyRBone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San FranciscoPLoS One201168e2368821897852
   PubMed Web of Science ®Google Scholar
• MulliganKGliddenDGonzalesPEffects of FTC/TDF on bone mineral densty in seronegative men from 4 continents: DEXA results of the global iPrEx Study [Abstract 94 LB]Presented at the 18th Conference on Retroviruses and Opportunistic Infections (CROI)Boston, USAFebruary 27 to March 2, 2011
   Google Scholar
• BoucherCACammackNSchipperPHigh-level resistance to (−) enantiomeric 2#-deoxy-3#-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptaseAntimicrob Agents Chemother199337223122347504909
   PubMed Web of Science ®Google Scholar
• TisdaleMKempSDParryNRLarderBARapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptaseProc Natl Acad Sci U S A199390565356667685907
   PubMed Web of Science ®Google Scholar
• MillerVStarkTLoeligerAELangeJMThe impact of the M184V substitution in HIV-1 reverse transcriptase on treatment responseHIV Med2002313514512010361
   PubMedGoogle Scholar
• WhitcombJMParkinNTChappeyCHellmannNSPetropoulosCJBroad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolatesJ Infect Dis2003188992100014513419
   PubMed Web of Science ®Google Scholar
• RousseauFSKahnJOThompsonMPrototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil)J Antimicrob Chemother20014850751311581229
   PubMed Web of Science ®Google Scholar
• BrennerBGCoutsinosDThe K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implicationsHIV Ther20093658359420190870
   PubMedGoogle Scholar
• ShaferRWSchapiroJMHIV-1 drug resistance mutations: an updated framework for the second decade of HAARTAIDS Rev200810678418615118
   PubMed Web of Science ®Google Scholar
• Doualla-BellFAvalosABrennerBHigh prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimensAntimicrob Agents Chemother20065041824185 Epub October 2, 200617015626
   PubMed Web of Science ®Google Scholar
• HurtCBEronJJCohenMSPre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost?Clin Infect Dis201153121265127021976467
   PubMed Web of Science ®Google Scholar
• LouieMHoganCHurleyADetermining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1--infected individualsAIDS2003171151115612819516
   PubMed Web of Science ®Google Scholar
• Van RompayKKJohnsonJABlackwoodEJSequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infectionRetrovirology200742517417971
   PubMed Web of Science ®Google Scholar
• KuritzkesDRQuinnJBBenoitSLDrug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patientsAIDS19961099759818853730
   PubMed Web of Science ®Google Scholar
• SupervieVGarcía-LermaJGHeneineWBlowerSHIV, transmitted drug resistance, and the paradox of the preexposure prophylaxisProc Natl Acad Sci U S A201010727123811238620616092
   PubMed Web of Science ®Google Scholar
• LeibowitzAAParkerKBRotheram-BorusMJA US policy perspective on oral preexposure prophylaxis for HIVAm J Public Health20111016982985 Epub April 14, 201121493945
   PubMed Web of Science ®Google Scholar
• LeeDHVielemeyerOPreexposure chemoprohylaxis for HIV prevention (letter to the editor)New Engl J Med2011364141372137321470026
   PubMedGoogle Scholar
• MyersGMMayerKHOral preexposure anti-HIV prophylaxis for high risk US populations: current considerations in light of new findingsAIDS Patient Care STDS2011252636721284497
   PubMed Web of Science ®Google Scholar
• GolubSAKowalczykWWeinbergerCLParsonsJTPreexposure prophylaxis and predicted condom use among high-risk men who have sex with menJ Acquir Immune Defic Syndr201054554855520512046
   PubMed Web of Science ®Google Scholar